334 results match your criteria: "Service hospitalo-universitaire de Psychiatrie[Affiliation]"
Gen Hosp Psychiatry
November 2023
MOODS Team, INSERM U1018, CESP, Université Paris-Saclay, Faculté de Medicine Paris-Saclay, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire des Pathologies Psychiatriques Résistantes, Z19, Centre hospitalier le Vinatier, 95 boulevard Pinel, F-69678 Bron Cedex, France.
J Nephrol
January 2024
Club des Jeunes Néphrologues, Paris, France.
Brain Stimul
June 2023
Pôle Hospitalo-Universitaire de Psychiatrie Adulte, Centre Hospitalier Guillaume Régnier, Rennes, France; Centre d'Investigation Clinique 1414, INSERM, Neuropsychiatrie du développement et du Comportement, CHU Rennes / Université de Rennes, Rennes, France.
Psychol Med
January 2024
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, Paris, F-94275, France.
Background: Major depression is associated with changes in plasma L-carnitine and acetyl-L-carnitine. But its association with acylcarnitines remains unclear. The aim of this study was to assess metabolomic profiles of 38 acylcarnitines in patients with major depression before and after treatment compared to healthy controls (HCs).
View Article and Find Full Text PDFBMJ Open
May 2023
Université de Poitiers, Centre de Recherches sur la Cognition et l'Apprentissage, Poitiers, Nouvelle-Aquitaine, France.
Introduction: Alcohol use disorder (AUD) ranks among the most prevalent psychiatric disorders worldwide. Despite current treatments, more than half of patients relapse within weeks after treatment. In animal models, exposure to environmental enrichment (EE) has been shown to be a promising approach to reduce relapse.
View Article and Find Full Text PDFEncephale
October 2024
Service hospitalo-universitaire de psychiatrie de Bicêtre, Mood Center Paris Saclay, Assistance publique-Hôpitaux de Paris, hôpitaux universitaires Paris-Saclay, hôpital de Bicêtre, 94275 Le Kremlin Bicêtre, France; MOODS Team, Inserm 1018, CESP (centre de recherche en épidémiologie et santé des populations), université Paris-Saclay, faculté de médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France.
Fundam Clin Pharmacol
December 2023
Université Paris-Saclay, Faculté de Pharmacie, UMR 1018 CESP, INSERM MOODS Team, Orsay, France.
Major depressive disorder (MDD) is a serious public health problem, as it is the most common psychiatric disorder worldwide. Antidepressant drugs increase adult hippocampal neurogenesis, which is required to induce some behavioral effects of antidepressants. Adult-born granule cells in the dentate gyrus (DG) and the glutamate receptors subunits 2 (GluN2B) subunit of N-methyl-D-aspartate (NMDA) ionotropic receptors play an important role in these effects.
View Article and Find Full Text PDFEncephale
April 2024
MOODS Team, Inserm, CESP, université Paris-Saclay, faculté de médecine Paris-Saclay, 94275 Le Kremlin-Bicêtre, France; Centre hospitalier le Vinatier, Bron, France; Union régionale des professionnels de santé libéraux, Auvergne Rhône-Alpes, France.
Introduction: The 2019 coronavirus (COVID-19) pandemic has caused a public health crisis worldwide. Concerns have been expressed about the rapid deterioration of mental health among primary care physicians among whom burnout already had a high prevalence prior to the pandemic. However, there is little data on private doctors during the pandemic.
View Article and Find Full Text PDFProg Neuropsychopharmacol Biol Psychiatry
August 2023
Fondation FondaMental, Créteil, France; Service Universitaire de santé mentale et physique, Centre Expert Dépression Résistante, CHU Sainte-Marguerite, APHM, Université Aix-Marseille, F-13009 Marseille, France; Aix Marseille Univ, CNRS, Centrale Marseille, Institut Fresnel, Marseille, France.
Background: Benzodiazepine long-term use (BLTU) is a public health challenge. We lack data on the consequences of LBTU on the trajectory of treatment-resistant depression (TRD).
Objective: To determine the prevalence of BLTU in a nationwide non-selected population of patients with TRD, to determine the rate of patients succeeding at withdrawing benzodiazepines at one year and to determine if persistent BLTU is associated with poorer mental health outcomes.
Biomedicines
February 2023
Laboratory of Immunology, Pasteur Institute, 75015 Paris, France.
Many and diverse autoimmune abnormalities have been reported in children with autism. Natural autoantibodies (NAAbs) play important immunoregulatory roles in recognition of the immune self. The objective of this study was to examine the presence of NAAbs in the sera of children with autism and across severity subgroups of autistic behavioral impairments.
View Article and Find Full Text PDFEncephale
August 2023
Groupe Hospitalier Paul-Guiraud (GHPG), 54, avenue de la République BP 20065, 94806 Villejuif cedex, France.
Schizophrenia (Heidelb)
February 2023
Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LPNC, 38000, Grenoble, France.
A large number of behavioral studies suggest that confidence judgments are impaired in schizophrenia, motivating the search for neural correlates of an underlying metacognitive impairment. Electrophysiological studies suggest that a specific evoked response potential reflecting performance monitoring, namely the error-related negativity (ERN), is blunted in schizophrenia compared to healthy controls. However, attention has recently been drawn to a potential confound in the study of metacognition, namely that lower task-performance in schizophrenia compared to healthy controls involves a decreased index of metacognitive performance (where metacognitive performance is construed as the ability to calibrate one's confidence relative to response correctness), independently of metacognitive abilities among patients.
View Article and Find Full Text PDFFront Psychiatry
February 2023
Université de Paris, INSERM U1266, Institute of Psychiatry and Neuroscience of Paris (IPNP), CNRS GDR3557, Paris, France.
Introduction: Folates, the main actors in one-carbon (C1) metabolism, are involved in synthesising monoamines and maintaining genomic stability. Previous studies support the association between C1 metabolism and schizophrenia. The main purpose of this study was to assess the prevalence of plasma folate, and/or vitamin B12 deficiencies and hyperhomocysteinemia in young patients with psychotic disorders.
View Article and Find Full Text PDFPsychiatry Res
March 2023
Université Paris-Saclay, AP-HP, Service Hospitalo-Universitaire de Psychiatrie, Hôpital de Bicêtre; Equipe MOODS, Inserm U1178, CESP (Centre de Recherche en Epidémiologie et Sante des Populations), Le Kremlin-Bicêtre, France.
Psychol Med
October 2023
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ. Paris-Saclay, Le Kremlin Bicêtre F-94275, France.
Background: Major depressive disorder (MDD) is a complex disorder with a significant public health burden. Depression remission is often associated with weight gain, a major risk factor for metabolic syndrome (MetS). The primary objective of our study was to assess prospectively the impact of response to antidepressant treatment on developing MetS in a sample of MDD patients with a current major depressive episode (MDE) and who are newly initiating their treatment.
View Article and Find Full Text PDFSchizophr Res
February 2023
Fondation Fondamental, Créteil, France; Centre Hospitalier de Versailles, Service Hospitalo-Universitaire de Psychiatrie d'Adultes et d'Addictologie, Le Chesnay, France; Université Paris-Saclay, Université Versailles Saint-Quentin-En-Yvelines, DisAP-DevPsy-CESP, INSERM UMR1018, 94807 Villejuif, France.
Background: Social metacognition is still poorly understood in schizophrenia, particularly its neuropsychological basis and its impact on insight and medication adherence. We therefore quantified social metacognition as the agreement between objective and subjective mentalization and assessed its correlates in a sample of individuals with schizophrenia spectrum disorders.
Methods: Participants consisted of 143 patients with schizophrenia or schizoaffective disorders who underwent a metacognitive version of a mentalization task, an extensive neuropsychological battery, and a clinical evaluation to assess their insight into illness and medication adherence.
Int J Mol Sci
December 2022
CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Université Paris-Saclay, F-94275 Le Kremlin Bicêtre, France.
Major depressive disorder (MDD) is the leading cause of disability worldwide. Treatment with antidepressant drugs (ATD), which target monoamine neurotransmitters including serotonin (5HT), are only modestly effective. Monoamine oxidase (MAO) metabolizes 5HT to 5-hydroxy indoleacetic acid (5HIAA).
View Article and Find Full Text PDFBMJ Open
December 2022
MESuRS Laboratory, Conservatoire National des Arts et Métiers, Paris, France.
Objectives: In modern professional life, mental health prevention and promotion have become a major challenge for decision-makers. Devising appropriate actions requires better understanding the role played by each work-related psychosocial factor (WPSF). The objective of this study was to present a relevant tool to hierarchise WPSFs that jointly takes into account their (impact on mental health) and their (the proportion of the population exposed to WPSF).
View Article and Find Full Text PDFBrain Behav Immun
February 2023
Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital CHU Montpellier, Montpellier, France; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France; Fondation FondaMental, France.
Evidences suggest that inflammation is increased in a subgroup of patients with depression. Moreover, increased peripheral inflammatory markers (cells and proteins) are associated with some, but not all depressive symptoms. On the other hand, similar studies on bipolar disorders mainly focused on blood cytokines.
View Article and Find Full Text PDFSchizophr Res
December 2023
Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, F-75014 Paris, France; MOODS Team, INSERM, CESP, Université Paris-Saclay, Faculté de Médecine Paris-Saclay, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Mood Center Paris Saclay, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital de Bicêtre, F-94275, France.